India's Biocon is following the footsteps of a lineup of the subcontinent's biopharma companies in spinning off its R&D operations into a separate company. Sun, Wockhardt and Ranbaxy have all announced similar plans, which analysts say can help attract investors into the sector. Biocon's Kiran Mazumdar Shaw also said that Biocon is also preparing to establish its own tablet formulation manufacturing facility. That work has been done by a contract manufacturer.
- check out the story from the Economic Times